arrow
M

Michael Barnett

the university of sydney
H指数:68
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term comparative outcomes in relapse activity and disability progression among anti-CD20 therapies in relapsing multiple sclerosis: An unanchored matching-adjusted indirect comparison

复发型多发性硬化中抗CD20疗法在复发活动与残疾进展方面的长期比较结局:一项非锚定匹配调整间接比较研究

2026-09-300
OA
Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

在复发缓解型多发性硬化中,针对临床静息期MRI病灶的治疗升级

Brain
IF11.7
2026-07-240
OAAI
Causal effects of multiple sclerosis therapies in left-truncated registry data

多发性硬化疗法在左截断登记数据中的因果效应

2026-07-210
PRE
Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion

多发性硬化疾病修正疗法对慢性病灶组织扩张的影响

2026-07-010
PRE
Real-World Effectiveness of Ocrelizumab in Relapsing Multiple Sclerosis: an MSBase Registry Sub-Study

奥法美南在复发型多发性硬化中的真实世界有效性:一项MSBase登记研究的子研究

2025-11-250
OAAI
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

造血干细胞移植与免疫重建疗法在复发型多发性硬化中的比较

Brain
IF11.7
2025-08-040
PRE
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

四年之后:MSBase妊娠、新生儿结局及女性健康登记册(2020–2024)中报告的妊娠与分娩结局

2025-07-070
PRE
Longitudinal Trajectories of Digital Cognitive Biomarkers for Multiple Sclerosis

多发性硬化症数字认知生物标志物的纵向轨迹

2025-02-010
OAAI
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

克拉屈滨与芬戈莫德,那他珠单抗,ocrelizumab和阿仑单抗在复发缓解型多发性硬化症中的疗效比较

2024-08-010
PRE
Improving multiple sclerosis lesion segmentation across clinical sites: A federated learning approach with noise-resilient training

改善跨临床站点的多发性硬化病变分割: 具有噪声弹性训练的联合学习方法

2024-06-011
OAAI
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse
2024-05-143
OAAI